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Molecular characterization of methicillin-resistant 
Staphylococcus aureus (MRSA) strains different from those 
of an endemic healthcare-associated clone was conducted 
over 13 years in Geneva, Switzerland. We demonstrated 
strain diversity, including clones rarely found in Europe. 
Local epidemiology of community-associated MRSA is di-
verse and is evolving by importation and transmission of 
new strains.
C
ommunity-associated methicillin-resistant Staphylo-
coccus aureus (CA-MRSA) is responsible for severe 
infections related to carriage of exotoxins such as the Pan-
ton-Valentine leukocidin (PVL), toxic shock syndrome 
toxin 1 (TSST-1), or exfoliatin A (1). Genetic content of 
CA-MRSA strains depends on the local epidemiology and 
was recently described as polyclonal (2) Another study re-
ported more uniformity in CA-MRSA lineages (3). We have 
recently evaluated prevalence of MRSA at hospital admis-
sion and showed a low CA-MRSA prevalence, a reservoir 
of asymptomatic carriers, and a high degree of CA-MRSA 
diversity (2). However, despite an increasing number of 
CA-MRSA infections in Europe (4), few, if any, studies 
have assessed long-term epidemiology of CA-MRSA in a 
geographically conﬁ  ned area. Awareness of secular trends 
in molecular features of CA-MRSA could affect public 
health and patient care. Therefore, our aim was to evalu-
ate genetic diversity and spread of non–multidrug-resistant 
MRSA strains isolated in Geneva over a 13-year period.
The Study
We selected 2 collections of strains with 151 nondu-
plicated MRSA isolates identiﬁ  ed in patients or carriers 
treated at our institution. The ﬁ  rst collection was from a 
retrospective review of laboratory records and included 
non–multidrug-resistant (gentamicin- and ciproﬂ  oxacin- 
susceptible) strains collected during 1993–2002 that had 
a phenotype different from the endemic healthcare-associ-
ated MRSA (HA-MRSA) strain in Geneva. The prevalent 
HA-MRSA clone in Geneva is sequence type (ST) 228-
MRSA-I (CC5), which shows resistance to gentamicin, 
ciproﬂ  oxacin, clindamycin, and erythromycin. HA-MRSA 
strain ST8-MRSA-IV has been sporadically introduced 
from France. This strain has the same phenotype as ST228-
MRSA-I (CC5) except for its susceptibility to gentamicin 
(5). We included all strains resistant to or with intermediate 
susceptibility to fusidic acid, a characteristic of many CA-
MRSA isolates in Europe.
The second collection was isolates selected from pa-
tients prospectively identiﬁ  ed as colonized or infected with 
CA-MRSA by the CA-MRSA surveillance program during 
2003–2005 (6). CA-MRSA was deﬁ  ned as any isolate with 
an antimicrobial drug resistance proﬁ  le different from the 
strain endemic in the Geneva healthcare setting and diag-
nosed in a patient without a history of hospitalization in the 
previous 12 months.
MRSA identiﬁ  cation was performed by using standard 
methods (7) according to Clinical and Laboratory Standard 
Institute recommendations (8) and conﬁ  rmed by quantita-
tive PCR (9). Genomic DNA isolated from 1 colony was 
tested by quantitative PCR for staphylococcal cassette 
chromosome mec (SCCmec) elements, accessory gene reg-
ulator group, and the PVL gene (10,11). Presence of type 
V cassette, TSST-1, and exfoliatin toxins was assessed by 
using speciﬁ  c oligonucleotides (sequences are available at 
www.genomic.ch/sup6.php). Multiple-locus variable-num-
ber tandem repeat analysis, which consisted of a multiplex 
PCR with 10 primer pairs, and multilocus sequence typing 
were performed as reported (11,12).
Since late 2002, all patient demographic and epidemi-
ologic data have been reviewed and recorded on a standard-
ized form by a public health nurse (6). For this analysis, we 
included only those patients who were seen at our institu-
tion or outpatient clinic.
A total of 92 strains from 51 patients (55% male, mean 
± SD age 37 ± 28 years) were obtained from the retrospec-
tive specimen collection. Fifty-nine isolates were obtained 
from clinical specimens and 33 from screening swabs. 
Among these isolates, 46 were obtained from skin and soft 
tissue samples and 13 from other body sites. A total of 59 
isolates were obtained from the prospective CA-MRSA 
surveillance system from 59 patients (mean ± SD age 33 ± 
21 years, male:female ratio 2.7).
Table 1 shows that most CA-MRSA strains isolated 
during 2002–2005 were associated with skin and soft tis-
sue infections. Most cases of infection or colonization were 
associated with migration or travel history. Four healthcare 
workers acquired CA-MRSA strains epidemiologically un-
related to each other. In 2 instances, family members of 
these workers were also affected.
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Strains were rarely resistant to clindamycin (5%), 
gentamicin (8% only in isolates recovered after 2002), 
or rifampicin (<1%). Susceptibility to cotrimoxazole was 
89% during the ﬁ  rst period and 100% during the second 
period. PVL-positive isolates remained multidrug suscep-
tible throughout the study period, and were distinct from 
our endemic nosocomial strain.
The Figure, panel A, shows the incidence of isolates 
fulﬁ  lling our entry criteria and the proportion of strains pro-
ducing PVL or harboring SCCmec IV or V. An increase in 
non–multidrug-resistant MRSA was observed during 1994–
1997 (incidence 2.3 cases/10,000 admissions in 1997), and a 
second peak was observed during 2002–2005 (incidence 4.3 
cases/10,000 admissions in 2004). Molecular characteriza-
tion of the 151 strains showed that 124 (82%) harbored ei-
ther SCCmec IV or V. A total of 92 isolates (61%) harbored 
at least 1 toxin gene, most frequently PVL (n = 60), followed 
by TSST-1 (n = 22) and exfoliatin A (n = 11). An isolate 
(ST149-MRSA-IV) from a Libyan patient harbored the PVL 
and TSST-1 genes (Table 2). A strain with PVL (ST80-
MRSA-IV) was isolated in 1994 from a 73-year-old man 
from Libya. A case of bacteremia with PVL-positive CA-
MRSA (ST80-MRSA-IV) was documented in a 28-year-old 
Tunisian woman who had an abscess of her left forearm in 
2000. No case of necrotizing pneumonia was observed.
From 1994 through 1999, we identiﬁ  ed 14 PVL-posi-
tive MRSA isolates. The Figure, panel B, shows that CA-
MRSA identiﬁ  ed during 1993–2002 consisted mainly of 
3 clonotypes (ST80, ST88, and ST5). After 2002, these 
strains were less frequent and the proportion of other clo-
notypes increased.
The online Appendix Figure (available from www.
cdc.gov/EID/content/14/2/304-appG.htm) shows that tox-
in-harboring strains segregated in 18 multiple-locus vari-
able-number tandem repeat analysis proﬁ  les and yielded 14 
multilocus sequences types. ST80 (n = 39) was the most 
abundant type (42% of toxin-producing isolates). Other 
clusters contained well-described ST5 (TSST-1 or PVL 
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Table 1. Demographic characteristics, types of infection, and 
epidemiologic profiles of 61 patients with CA-MRSA colonization 
or infection, Geneva University Hospitals, 2002–2005* 
Characteristic Value
Demographic data 
  Mean ± SD age, y  33 ± 21 
 Male  35  (57) 
  Immigrant, foreign origin or residency  
 outside  Switzerland 
25 (41) 
  Recent history of travel before CA-MRSA  
 isolation 
29 (48) 
  Institutionalized (prison, nursing home,  
 asylum-seeker  camp) 
11 (18) 
 Healthcare  worker  4  (7) 
Type of infection/colonization 
  Primary cutaneous abscess or pyoderma  27 (44) 
  Wound infection  4 (7) 
 Impetigo  3  (5) 
 Other  1  (2) 
 Colonization  26  (43) 
Site of skin infection (n = 27)   
  Head and face  6
 Upper  extremity  6
  Trunk and buttock  7
 Lower  extremity  8
Other clinical features   
  Presence of >1 other medical condition  16 (26) 
  Previous exposure (<6 mo) to antimicrobial  
 drug 
16 (26) 
 Case-fatality  rate  0
*Values are no. (%) of patients unless otherwise indicated. For 2 patients, 
no microbiologic specimen was available for molecular characterization. 
See also supplementary material (available from 
www.genomic.ch/sup6.php). CA-MRSA, community-associated methicillin-
resistant Staphylococcus aureus.
Figure. Incidence of non–multidrug-resistant methicillin-resistant 
Staphylococcus aureus (MRSA) strains, Geneva, Switzerland, 
1993–2005. A) Number of strains collected since 1993 showing an 
atypical multidrug-susceptible phenotype (white bars). Also shown 
are the number of SCCmec IV and V (circles) isolates and number 
of strains containing Panton-Valentine leukocidin (PVL) (triangles). 
B) Evolution of the 3 most abundant clonotypes (ST80, ST88, and 
ST5). Despite a constant number of strains isolated since 2002, 
the proportion of these clones has decreased, which suggests 
increasing diversity of clones in our population of community-
acquired MRSA.positive), ST30, and ST8 (USA300) strains harboring the 
PVL gene. 
Several epidemiologically linked cases were identiﬁ  ed 
in the second period (online Appendix Figure): a cluster of 
6 family members with recurrent furunculosis over 5 years 
(ST80-MRSA-IV), 4 smaller family clusters with the same 
clone, and 3 family clusters with other clonally related 
strains (ST5-MRSA-IV, ST59-MRSA-V, ST1-MRSA-
V). Two inmates incarcerated in the same cell of the Ge-
neva prison had abscesses caused by the ST8-MRSA-IV 
(USA300) strain. One outbreak involved 5 neonates and 
2 mothers colonized or infected with ST5-MRSA-IV har-
boring the PVL gene (5). We also observed a cluster of 5 
patients from Kosovo infected or colonized with a PVL-
producing strain (ST152-MRSA-V) resistant to gentamicin 
and amikacin.
Strains lacking toxins (online Appendix Figure, panel 
B) showed a wide diversity of patterns. Most isolates (n = 
33) were obtained from the ﬁ  rst stain collection and showed 
many different genetic backgrounds (n = 21).  
Conclusions
We studied 2 collections of non-multiresistant MRSA 
strains identiﬁ  ed over a 13-year period at our institution. 
Our analysis showed that sporadic PVL-positive CA-MRSA 
has been isolated in Geneva since 1994; the largest cluster 
corresponded to ST 80 (SCCmec IV, PVL positive); the 
PVL gene is disseminated in many genetic backgrounds; 
strains showed diversity of genomic content; several epi-
demiologic clusters were identiﬁ  ed; and many cases were 
linked to migration and travel.
Our data showed that resistance to fusidic acid or sus-
ceptibility to gentamicin should not be used as phenotypic 
criteria for CA-MRSA in Europe. For example, gentami-
cin-resistant ST152-MRSA-V found in 5 patients from 
Kosovo is common.
The number of genetic proﬁ  les  identiﬁ  ed  appears 
particularly high, which is similar to proﬁ  les described in 
European countries, northern Africa, Oceania, and the 
Americas. In contrast to CA-MRSA epidemiology de-
scribed as homogeneous in Australia (13), some parts of 
the United States (14), or Sweden (15), our local epidemi-
ology appears more heterogeneous.
Frequently observed importation of CA-MRSA may 
enhance genetic exchange between strains and supports the 
need for active surveillance. Most CA-MRSA remained 
susceptible to many antimicrobial drugs, but genetic ex-
change between strains resulting in acquisition of resis-
tance determinants in CA-MRSA or transfer of virulence 
markers into HA-MRSA are important concerns.
Our study has limitations. First, we used 2 strain col-
lections. The collection obtained before 2003 may have 
omitted gentamicin-resistant CA-MRSA strains (e.g., 
ST152). Second, retrospective case ascertainment does not 
distinguish invasive from colonizing strains in all patients. 
Finally, we cannot exclude detection bias caused by our 
active MRSA screening policy (6,7).
In summary, increasing incidence of PVL-producing 
type IV CA-MRSA isolates is worrisome and indicates 
emergence of new MRSA lineages with a particular ﬁ  t-
ness for community transmission. Further epidemiologic 
and molecular typing studies are needed to document CA-
MRSA carriage and infection rates and implement adequate 
infection control guidelines.
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Table 2. Molecular characteristics of the non–multidrug-resistant methicillin-resistant Staphylococcus aureus isolates, Geneva 
University Hospitals, 2002–2005* 
agr type 
Isolates  No. strains  PVL  Exfoliatin toxin A  TSST-1  1 2 3 4  Main MLST types 
SCCmec I  21  0 0 11  9  11  1  0  5,149
SCCmec  II  1  0  0  0  0 1 0 0  ND 
SCCmec  III  1  0  0  0  0 0 1 0  ND 
SCCmec IV†  109  53  11 9  20  24  65  0  1, 5, 8, 22, 30, 72, 
80, 85, 88, 149 
SCCmec V  15  6 0 1  8‡  3  4  0  1, 30, 59, 85, 152 
SCCmec NT  4  1  0  1  1  1  2  0  ND 
Total§ 151  60 11 22  38  40  73  0   
*PVL, Panton-Valentine leukocidin; TSST-1, toxic shock syndrome toxin 1; agr, accessory gene regulator; MLST, multilocus sequence typing; SCCmec, 
staphylococcal cassette chromosome mec; ND, not determined; NT, nontypeable. 
†Two isolates had recombinases identical to SCCmec IVe on the basis of sequence information; 4 isolates were not typeable. 
‡One isolate was characterized after PCR amplification and sequencing as previously described (12).
§A total of 92 strains had toxins, but the total number of toxin genes detected was 93 because 1 isolate contained PVL and TSST-1. MRSA, Geneva, Switzerland, 1993–2005
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